NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

中國的Dexmedetomidine市場分析 (2021年∼2025年)

Investigation Report on China's Dexmedetomidine Market 2021-2025

出版商 China Research and Intelligence 商品編碼 1010202
出版日期 內容資訊 英文 50 Pages
商品交期: 最快1-2個工作天內
價格
中國的Dexmedetomidine市場分析 (2021年∼2025年) Investigation Report on China's Dexmedetomidine Market 2021-2025
出版日期: 2021年06月08日內容資訊: 英文 50 Pages
簡介

Dexmedetomidine,是選擇性高的α2-腎上腺素受體的促效劑,主要用於受到全身麻醉的外科患者的氣管插管及人工呼吸器的鎮靜。2009年也在中國登記、核可,2020年時有5家公司進入市場。

中國國內的Dexmedetomidine的銷售量,從2016年到2019年踏實增加。尤其是,受2018年的中國政府的 "4+7" 集中採購的影響,達成以數量為準與前一年同期比較29.66%,以金額為準與前一年同期比較近18%的成長。但2020年,由於新型冠狀病毒感染疾病 (COVID-19)的影響,減少了9億8400萬元 (與前一年同期比較減少3.45%) 。2016年∼2020年的年複合成長率達到11.8%非常高的水準。今後,由於COVID-19舒緩和性能高等預計繼續擴大趨勢。

本報告提供中國的Dexmedetomidine的市場相關分析,產品的概要和授權情形,整體市場規模趨勢預測,各地區的詳細趨勢,市場價格趨勢預測,主要企業的簡介與市場佔有率,主要的推動及阻礙市場要素等彙整資訊,為您概述為以下內容。

目錄

第1章 Dexmedetomidine的相關概念

  • Dexmedetomidine的適應症
  • 中國國內的Dexmedetomidine的開發趨勢
  • 中國政府的Dexmedetomidine的核準情況
  • COVID-19對中國的Dexmedetomidine銷售的影響

第2章 中國國內的Dexmedetomidine銷售趨勢 (2016年∼2020年)

  • Dexmedetomidine的銷售額
    • 整體銷售額
    • 各地區的銷售額
  • Dexmedetomidine的銷售量
    • 整體銷售量
    • 各地區的銷售量
  • 中國國內的Dexmedetomidine銷售趨勢:各劑型 (2016年∼2020年)
    • 投入的藥劑
    • 其他的劑型

第3章 中國的Dexmedetomidine主要製造商分析 (2020年)

  • 主要Dexmedetomidine製造商市場佔有率分析
    • 市場佔有率:銷售額為基礎
    • 市場佔有率:銷售量為基礎
  • Yangtze River Pharmaceutical Group Co.,Ltd.
    • 企業簡介
    • 中國的Dexmedetomidine銷售趨勢
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Jiangsu Nhwa Pharmaceutical Co., Ltd.
  • Sichuan Guorui Pharmaceutical Co., Ltd.
  • Cisen Pharmaceutical Co., Ltd.

第4章 中國的Dexmedetomidine的價格趨勢:各主要製造商 (2020年∼2021年)

  • Yangtze River Pharmaceutical Group Co.,Ltd. (Youbituo)
  • Jiangsu Hengrui Medicine Co., Ltd. (Aibeining)
  • Jiangsu Nhwa Pharmaceutical Co., Ltd. (Yisi)
  • Sichuan Guorui Pharmaceutical Co., Ltd. (Leweijia)
  • Cisen Pharmaceutical Co., Ltd. (Chenjiao)

第5章 中國的Dexmedetomidine市場未來展望 (2021年∼2025年)

  • 左右中國的Dexmedetomidine市場趨勢的要素
    • COVID-19對中國的Dexmedetomidine市場的影響
    • 市場促進因素和機會
    • 市場威脅與課題
  • 市場規模的預測
  • 市場趨勢的預測
目錄
Product Code: 2106530

Dexmedetomidine is a highly selective α2-adrenergic receptor agonist. It is mainly used clinically for the sedation of tracheal intubation and mechanical ventilation in surgical patients undergoing general anesthesia. It was developed by Abbott and Orion Corp. According to CRI's market research, as of the end of 2020, the original drug of Dexmedetomidine has not been listed in China. In 2009, Jiangsu Hengrui Medicine Co., Ltd. first imitated the drug and was approved to be listed in China. By 2020, there are 5 manufactures in Chinese Dexmedetomidine market, of which Yangtze River Pharmaceutical is the main manufacture.

According to CRI's market research, the sales value of Dexmedetomidine in the Chinese market increased year by year at a steady growth rate from 2016 to 2019. Especially, affected by the "4+7" centralized procurement by the Chinese government in 2018, its sales volume increased by 29.66% year-on-year, and sales increased by nearly 18% year-on-year. Due to the impact of COVID-19 on the overall diagnosis and treatment services of Chinese hospitals, the sales value of Dexmedetomidine in the Chinese market decreased to CNY 984 million in 2020, a year-on-year decrease of 3.45%. The CAGR of sales value of Dexmedetomidine in the Chinese market is 11.8% in 2016 to 2020, which is a very high level.

CRI expects that the sales of Dexmedetomidine in the Chinese market will have a restorative growth from 2016 to 2020 as the alleviation of the COVID-19 epidemic. In addition, as a new type of α2 adrenergic receptor agonist, Dexmedetomidine has significant advantages such as high selectivity, strong sedative and analgesic effects, anti-anxiety and hemodynamic stability. Based on these advantages, the sales value and sales volume of Dexmedetomidine still have room to rise.

Topics Covered:

  • The impact of COVID-19 on China's Dexmedetomidine market
  • Sales value of China's Dexmedetomidine 2016-2020
  • Competitive landscape of China's Dexmedetomidine market
  • Prices of Dexmedetomidine in China
  • Prices of Dexmedetomidine in China by regions and manufacturers
  • Analysis on factors affecting the development of China's Dexmedetomidine market
  • Prospect of China's Dexmedetomidine market from 2021 to 2025

Table of Contents

1 Relevant Concepts of Dexmedetomidine

  • 1.1 Indications for Dexmedetomidine
  • 1.2 Development of Dexmedetomidine in China
  • 1.3 Governmental Approval of Dexmedetomidine in China
  • 1.4 The Impact of COVID-19 on Dexmedetomidine Sales in China

2 Sales of Dexmedetomidine in China, 2016-2020

  • 2.1 Sales Value of Dexmedetomidine
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value by Region
  • 2.2 Sales Volume of Dexmedetomidine
    • 2.2.1 Overall Sales Volume
    • 2.2.2 Sales Volume by Region
  • 2.3 Sales of Dexmedetomidine by Dosage Form in China, 2016-2020
    • 2.3.1 Injection
    • 2.3.2 Analysis of Other Dosage Forms

3 Analysis of Major Dexmedetomidine Manufacturers in China in 2020

  • 3.1 Analysis of Market Share of Major Dexmedetomidine Manufacturers
    • 3.1.1 Investigation on Market Share by Sales Value
    • 3.1.2 Investigation on Market Share by Sales volume
  • 3.2 Yangtze River Pharmaceutical Group Co.,Ltd.
    • 3.2.1 Enterprise Profile
    • 3.2.2 Sales of Youbituo (Yangtze River Pharmaceutical Group Co.,Ltd.'s Dexmedetomidine) in China
  • 3.3 Jiangsu Hengrui Medicine Co., Ltd.
    • 3.3.1 Enterprise Profile
    • 3.3.2 Sales of Aibeining (Jiangsu Hengrui Medicine Co., Ltd.'s Dexmedetomidine) in China
  • 3.4 Jiangsu Nhwa Pharmaceutical Co., Ltd.
    • 3.4.1 Enterprise Profile
    • 3.4.2 Sales of Yisi (Jiangsu Nhwa Pharmaceutical Co., Ltd.'s Dexmedetomidine) in China
  • 3.5 Sichuan Guorui Pharmaceutical Co., Ltd.
    • 3.5.1 Enterprise Profile
    • 3.5.2 Sales of Leweijia (Sichuan Guorui Pharmaceutical Co., Ltd.'s Dexmedetomidine) in China
  • 3.6 Cisen Pharmaceutical Co., Ltd.
    • 3.6.1 Enterprise Profile
    • 3.6.2 Sales of Chenjiao (Cisen Pharmaceutical Co., Ltd.'s Dexmedetomidine) in China

4 Prices of Dexmedetomidine for Different Manufacturers in China, 2020-2021

  • 4.1 Yangtze River Pharmaceutical Group Co.,Ltd. (Youbituo)
  • 4.2 Jiangsu Hengrui Medicine Co., Ltd. (Aibeining)
  • 4.3 Jiangsu Nhwa Pharmaceutical Co., Ltd. (Yisi)
  • 4.4 Sichuan Guorui Pharmaceutical Co., Ltd. (Leweijia)
  • 4.5 Cisen Pharmaceutical Co., Ltd. (Chenjiao)

5 Prospect of Chinese Dexmedetomidine Market, 2021-2025

  • 5.1 Influential Factors of Chinese Dexmedetomidine Market Development
    • 5.1.1 The Impact of COVID-19 on Chinese Dexmedetomidine Market
    • 5.1.2 Market Drivers and Opportunities
    • 5.1.3 Market Threats and Challenges
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Market Trend

List of Charts

  • Chart Patent Information About Dexmedetomidine Injection Registration in China
  • Chart Sales Value of Dexmedetomidine Injection over the World
  • Chart Sales Value of Dexmedetomidine Injection in China, 2016-2020
  • Chart Sales Value of Dexmedetomidine Injection in China by Region, 2016-2020
  • Chart Sales Volume of Dexmedetomidine Injection in China, 2016-2020
  • Chart Sales Volume of Dexmedetomidine Injection in China by Region, 2016-2020
  • Chart Market Share by Sales Value of Top Dexmedetomidine Injection Manufacturers in China, 2016-2020
  • Chart Sales Value and Volume of Youbituo in China, 2016-2020
  • Chart Sales Value and Volume of Aibeining in China, 2016-2020
  • Chart Sales Value and Volume of Yisi in China, 2016-2020
  • Chart Sales Value and Volume of Leweijia in China, 2016-2020
  • Chart Sales Value and Volume of Chenjiao in China, 2016-2020
  • Chart Referential Prices of Youbituo in China by Region, 2020-2021
  • Chart Referential Prices of Aibeining in China by Region, 2020-2021
  • Chart Referential Prices of Yisi in China by Region, 2020-2021
  • Chart Referential Prices of Leweijia in China by Region, 2020-2021
  • Chart Referential Prices of Chenjiao in China by Region, 2020-2021
  • Chart Forecast on Sales Value of Dexmedetomidine Injection in China, 2021-2025
  • Chart Forecast on Sales Volume of Dexmedetomidine Injection in China, 2021-2025